▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2065 by analyst upside · 2026-06-27
CTKB
Cytek Biosciences, Inc.
Healthcare · Market Cap $579M · P/E 0x
ANALYST PRICE TARGET
+27.0%
implied upside to consensus target
Current Price $4.48
Consensus Target $5.69
Bull Target $7.5
Bear Target $4.75
Analysts Covering 4
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
1
Hold
2
Sell
0
52-Week Low $3.09
52-Week High $6.18
YTD Return -8.9%
FUNDAMENTALS
Market Cap $579M
P/E Ratio (TTM) N/A
Forward P/E 23.6x
EPS (TTM) $-0.58
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $204M
Profit Margin -36.2%
52-WEEK RANGE
52-Week Low $3.09
52-Week High $6.18
Current Price $4.48
Bear Target $4.75
Bull Target $7.5
● Now $4.48 ● Target $5.69
TRADING DATA
Avg Volume 1.2M
YTD Return -8.9%
Analyst Count 4
Consensus Buy
Upside to Target +27.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Cytek Biosciences, Inc. (CTKB) is currently trading at $4.48 with a Wall Street consensus price target of $5.69, implying potential upside of 27.0% over the next 12 months. 4 analysts currently cover CTKB, with a consensus rating of Buy — 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $7.5, while the most cautious has a target of $4.75.

CTKB operates in the Healthcare sector with a market capitalisation of $579M. The stock is down 8.9% year-to-date and is currently trading near the lower end of its 52-week range of $3.09 – $6.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RIGL +40.1%
Rigel Pharmaceuticals, Inc.
$716M · P/E 2.0x · Buy
IRWD +47.7%
Ironwood Pharmaceuticals, Inc.
$680M · P/E 6.3x · Buy
TCMD +30.4%
Tactile Systems Technology, Inc.
$683M · P/E 32.2x · Buy
GMRS +33.3%
GMR Solutions Inc.
$785M · P/E 7.6x · Buy
BVS +51.3%
Bioventus Inc.
$663M · P/E 23.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CTKB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Stephens & Co. — Reiterated
Overweight → Overweight 2026-05-13 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
TD Cowen — Reiterated
Buy → Buy 2026-01-08 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2025-11-11 14% win rate (7 calls)
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2025-05-28 Building track record
Goldman Sachs — Reiterated
Sell → Sell 2025-05-12 Building track record
Stephens & Co. reit
Overweight → Overweight 2025-03-19 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2025-03-04 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →